| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Digitoxigenin acts by inhibiting the sodium-potassium ATPase pump in cell membranes, leading to an increase in intracellular sodium and calcium levels. This enhances cardiac contractility and promotes diuresis. It binds to the ATPase pump, disrupting its normal function and leading to the accumulation of intracellular ions.
|
|---|---|
| ln Vitro |
In vitro, digitoxigenin inhibits Na+/K+ ATPase activity, which is crucial for cell membrane potential and ion transport. It may induce apoptosis in cancer cells by activating caspase-dependent pathways and inhibiting cell proliferation. It has potential anti-herpes and cytotoxic activity.
|
| ln Vivo |
In vivo, digitoxigenin functions as a precursor to digitoxin, which is used in the treatment of heart failure. Its ability to modulate ion transport and induce apoptosis makes it useful for studying cellular signaling pathways. Topical digitoxigenin has been studied for wound healing.
|
| Enzyme Assay |
In vitro enzyme assays for digitoxigenin typically measure its ability to inhibit Na+/K+ ATPase activity. The enzyme is incubated with ATP and sodium/potassium ions in the presence of increasing concentrations of the compound. ATPase activity is measured by the release of inorganic phosphate using colorimetric methods. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for digitoxigenin involve treating various cell lines with the compound and measuring cell viability, apoptosis, and ion flux. Intracellular calcium levels are measured using fluorescent indicators. Apoptosis is assessed by caspase activation and Annexin V staining. The compound's effects on cell proliferation and survival are quantified.
|
| Animal Protocol |
In vivo animal studies for digitoxigenin are typically conducted in the context of cardiac glycoside research. The compound is administered to animal models to study its effects on cardiac contractility, blood pressure, and diuresis. Its cardiotonic effects are assessed by measuring hemodynamic parameters. Wound healing studies have also been conducted.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of digitoxigenin are characteristic of cardenolides. As the aglycon of digitoxin, it is less polar than its glycoside derivatives. It is absorbed and distributed to tissues, where it inhibits Na+/K+ ATPase. Metabolism occurs in the liver. The compound has a molecular weight of 374.51 g/mol and a molecular formula of C23H34O4.
|
| Toxicity/Toxicokinetics |
Digitoxigenin is a toxic compound due to its cardiac glycoside activity. Overdose can cause cardiac arrhythmias and other serious effects. It should be handled with caution in laboratory settings. Appropriate safety precautions should be taken when handling the compound.
|
| Additional Infomation |
Digitoxigenin aglycone is a 5β-cardiac glycoside with hydroxyl substituents at the 3β and 14β positions and a double bond unsaturation at C(20)-C(22). It is a 3β-hydroxy steroid and a 14β-hydroxy steroid. It is derived from the hydride of 5β-cardiac glycoside.
Digitoxigenin aglycone is a cardiac glycoside and is the aglycone of Digitoxigenin. Digitoxigenin aglycone has been reported to exist in Streptocaulon juventas, Beaumontia grandiflora and other organisms with relevant data. 3β,14-Dihydroxy-5β-card-20(22)enolactone. A cardiac glycoside and is the aglycone of Digitoxigenin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin. Digitoxigenin is a biochemical assay reagent for the study of cardiac glycosides. It is a precursor to digitoxin, which is used in the treatment of heart failure. The compound is not approved for therapeutic use but is a valuable research tool for studying Na+/K+ ATPase and cardiac glycoside pharmacology. It is also known as Thevetigenin and Echujetin. |
| Molecular Formula |
C23H34O4
|
|---|---|
| Molecular Weight |
374.52
|
| Exact Mass |
374.245
|
| CAS # |
143-62-4
|
| PubChem CID |
4369270
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
549.3±50.0 °C at 760 mmHg
|
| Melting Point |
253-255 °C (dec.)(lit.)
|
| Flash Point |
188.2±23.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
2.79
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
27
|
| Complexity |
686
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O([H])[C@]12C([H])([H])C([H])([H])[C@]([H])(C3=C([H])C(=O)OC3([H])[H])[C@@]1(C([H])([H])[H])C([H])([H])C([H])([H])[C@]1([H])[C@@]3(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[C@@]3([H])C([H])([H])C([H])([H])[C@@]21[H])O[H]
|
| InChi Key |
XZTUSOXSLKTKJQ-CESUGQOBSA-N
|
| InChi Code |
InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1
|
| Chemical Name |
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
|
| Synonyms |
Thevetigenin Cerberigenin Digitoxigenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~333.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6701 mL | 13.3504 mL | 26.7008 mL | |
| 5 mM | 0.5340 mL | 2.6701 mL | 5.3402 mL | |
| 10 mM | 0.2670 mL | 1.3350 mL | 2.6701 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
